SML1628

LMT-28

≥98% (HPLC)

• Synonym(e): (4S)-3-[(2S,3S)-3-Hydroxy-2-methyl-4-methylene-1-oxononyl]-4-(1-methylethyl)-2-oxazolidinone
• Empirische Formel (Hill-System): C₁₇H₂₉NO₄
• CAS-Nummer: 1239600-18-0
• Molekulargewicht: 311.42
• UNSPSC-Code: 12352200
• PubChem Substanz-ID: 329825512
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: oil
• Farbe: colorless to light yellow, oil
• Versandbedingung: wet ice
• Lagertemp.: −20°C
• SMILES String: CC(C)[C@H](N1C([C@@H](C)[C@H](O)C(CCCCC)=C)=O)COC1=O
• InChI: 1S/C17H29NO4/c1-6-7-8-9-12(4)15(19)13(5)16(20)18-14(11(2)3)10-22-17(18)21/h11,13-15,19H,4,6-10H2,1-3,5H3/t13-,14+,15+/m0/s1
• InChIKey: UDXWSYOXIRPYFK-RRFJBIMHSA-N

Beschreibung

Biochem./physiol. Wirkung

LMT-28 is a derivative of oxazolidinone. It has the ability to repress the activation of signal transducer and activator of transcription 3 (STAT3) stimulated by interleukin 6 (IL-6). Orally administered LMT-28 reduced arthritis and acute pancreatitis stimulated by collagen in mice pathologic models.

LMT-28 is an IL-6 antagonist that targets the IL-6 Receptor β subunit, Glycoprotein 130 (gp130). Its binding to gp130) results in inhibition of IL-6 activation, and downregulation of levels of p-STAT3. LMT-28 was shown to stimulate phosphorylation of STAT3 and JAK2 protein. IL-6 dysregulation is involved in inflammation and cancers. LMT-28 had inhbitory activity against IL-6–dependent TF-1 cell proliferation and also had therapeutic effect against pancreatitis.

Sicherheitshinweise

• Lagerklassenschlüssel: 10 - Combustible liquids
• WGK: WGK 3